The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
B | Blood and blood forming organs | |
2
|
B03 | Antianemic preparations | |
3
|
B03X | Other antianemic preparations | |
4
|
B03XA | Other antianemic preparations | |
5
|
B03XA06 |
| Active Ingredient |
|---|
|
Luspatercept, an erythroid maturation agent, is a recombinant fusion protein that binds selected transforming growth factor-β (TGF-β) superfamily ligands. By binding to specific endogenous ligands (e.g. GDF-11, activin B) luspatercept inhibits Smad2/3 signalling, resulting in erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts) in the bone marrow. |
| Document | Type | Information Source | |
|---|---|---|---|
| REBLOZYL Powder for solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| REBLOZYL Powder for solution for injection / infusion | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.